Posterior Reversible Encephalopathy Syndrome (PRES) in a Patient Treated With a Novel Combination Treatment With Anti PDL1 Antibody (Durvalumab) and VEGFR2 Antibody (Ramucirumab). acmcr 2020, 4 (1), 8-14.